Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clemastine Treatment in Individuals With Williams Syndrome
Sponsor: Sheba Medical Center
Summary
This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.
Official title: Clemastine Treatment in Individuals With Williams Syndrome- a Double-blind Placebo Control to Assess the Safety and Efficacy
Key Details
Gender
All
Age Range
6 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-04-01
Completion Date
2026-07
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Open Label Clemastine with a blinded randomize withdrawal
Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
Locations (2)
Child and Adolescent Psychiatry Unit, Sheba Medical Center
Ramat Gan, Israel
Tel Aviv University
Tel Aviv, Israel